Biotech

It turns out you can have too much of a good thing. The 1,000-plus immunotherapy trials and competition to develop proprietary versions of virtually the same drugs may prove inhibitory to cancer research, according to the New York Times. The conditions leave clinical researchers competing for the...

Under a new deal between the U.S. Food and Drug Administration and the medtech device industry, manufacturers would be required to report device defects within three months of detecting their potential threat of injury ━ a tripling of the current 30-day reporting period. Events requiring recall or...

After some huge swings in the past three years, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) has been relatively quiet for the past few months, trading mostly sideways within a very narrow range. The extended consolidation period may mean the IBB’s next breakout will be a big...

Biotech stocks are seeking to regain some semblance of normalcy after Wednesday's Trump-inspired selloff. Much against market perceptions of a biotech-friendly President-elect Donald Trump stance, he hit out at the sector, with a vague message that suggested he is going to clamp down on drug...

Putting personal politics aside for a moment, it is not unreasonable to assume that investors who were long biotechnology stocks and exchange-traded funds into Election Day are happy with the outcome. Leading up to Election Day, Democratic nominee Hillary Clinton and her harsh rhetoric against high...

A sector rotation is common, particularly in times of market volatility. However, picking the timing and the right sector is always a concern for investors. "There's always money coming out of something, going into something else," Joel Elconin, co-host of Benzinga's PreMarket Prep, said during...

Valeant Pharmaceuticals Intl Inc. (NYSE: VRX) shares plunged nearly 9 percent in Monday's after-hours trading session following word the company may have to restate financial results, before recovering slightly. The potential restatement, according to sources, would come on the heels of a...

The Biotechnology sector has been wracked with uncertainty over the past year as market turmoil has weighed on the industry as a whole. Many investors have become skeptical of the industry's future and whether or not it can continue to produce gains of around 7 percent as it has done over the...

RBC Capital analyst Adnan Butt recently named 12 biotech stocks with major binary events expected in 2016. Here’s a breakdown of the full list. Aerie Pharmaceuticals Inc (NASDAQ: AERI): Phase 3 data for Rhopressa and Roclatan Aptose Biosciences Inc (NASDAQ: APTO): Phase 1 data for...

Earlier this year pharmaceutical firms began to worry about the upcoming 2016 elections after Presidential hopeful Hillary Clinton announced plans to regulate drug pricing further to ensure that healthcare costs don't skyrocket. While that proposal was well received by consumers, drug...

Shares of KaloBios Pharmaceuticals Inc (NASDAQ: KBIO) surged more than 1,000 percent early Thursday morning. KaloBios announced that a group of investors (led by notable biotech investor Martin Shkreli) have acquired 50 percent of the outstanding shares. A trader in Arizona named Joe...

Eli Lilly and Co (NYSE: LLY) shares are plunging nearly 8.0 percent in early trading on Monday after the company announced that it is discontinuing development of cardiovascular disease treatment drug evacetrapib because of disappointing efficacy. Here’s a look at what shareholders can...

JMP analysts said in a note on Monday that last week's biotech sector was "one of the busiest we can recall in quite some time." The biotech sector is "as, or more attractive" than it was in April. The sector remains "reasonable" on a PE and PEG basis. In a report published Monday, JMP Securities...

REITs can offer investors exposure to iconic assets, organic growth prospects and diversified assets. BMO Capital Markets initiated coverage of four unique REITs with Outperform ratings. All four stocks offer potential returns of 24 to 31 percent. In separate reports published Wednesday,...